Jiangsu Wanbang, a subsidiary of Fosun Pharmaceutical, withdraws the application for production of new diabetes drugs
-
Last Update: 2016-02-11
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Fosun Pharmaceutical (600196) (02196) announced that recently, according to the latest drug review policy of the State Food and drug administration, and combined with the actual situation, Jiangsu Wanbang biochemical medicine, the holding subsidiary of the company, submitted an application to the Jiangsu food and Drug Administration for the withdrawal of the application for production of recombined laiproline insulin injection and its API (the new drug) The new drug is mainly suitable for the treatment of diabetic patients who need insulin to maintain normal blood glucose homeostasis As of January 31, 2016, Jiangsu Wanbang has invested about 49 million yuan in research and development of the new drug at this stage Fosun Pharmaceutical means that the withdrawal of the application for production of the new drug will not have a significant impact on the current and future operation of the group Jiangsu Wanbang will decide the re application of the new drug according to the latest review policies and requirements of the State Food and Drug Administration and the update of the clinical trial data of the new drug
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
